NaPro, Abbott, Bristol-Myers cancer news

NPRO and licensee ABT settled their ongoing paclitaxel litigation with BMY, and NPRO and BMY non-exclusively cross-licensed certain paclitaxel patents. NPRO received a license from BMY to market gener...